TERRASCEND EXPANDS ITS VALHALLA PRODUCT LINEUP TO INCLUDE ONE OF THE FIRST 100MG EDIBLES IN THE KEYSTONE STATE
TORONTO, Jan. 24, 2024 — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced the expansion of its Valhalla product offering to include one of the first 100mg edibles in The Keystone State. Valhalla’s 100mg quick-acting, high-potency troches will land on store shelves on February 2nd. The Valhalla Extra Strength Troches will be available at all Apothecarium locations and additional dispensaries throughout Pennsylvania.
The innovative Valhalla Troches first debuted in Pennsylvania last fall, quickly becoming a patient favorite. Currently available in 5mg, 10mg, and 50mg of THC flavor-forward varieties, including Blue Raspberry (Indica), Orange (Sativa), and Watermelon (Hybrid), Valhalla Troches are supplied in convenient, resealable packaging optimal for patients on the go. The new 100mg troches will be available in Grape (Indica), Pineapple (Sativa), and Green Apple (Hybrid).
“We are thrilled to launch Valhalla high-dose troches into the Pennsylvania market,” said BJ Carreta, TerrAscend’s senior vice president of marketing. “Patients’ expectations are rising, and we are excited to expand our offering of high-quality and innovative cannabis products in this important state.”
TerrAscend cultivates, manufactures, and distributes Valhalla, Gage, Ilera, Legend, and Kind Tree cannabis offerings across Pennsylvania. The Company has scaled operations in five core markets, including the keystone state. To learn more about where to find Valhalla Troches of all dosage levels in Pennsylvania, visit apothecarium.com. For a deeper dive into TerrAscend’s operations in The Keystone State, please visit terrascend.com.
About TerrAscend Corp.
TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan, and California through TerrAscend Growth Corp. and retail operations in Canada through TerrAscend Canada, Inc. (“TerrAscend”). TerrAscend operates The Apothecarium, Gage and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.
While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.
